Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial-March 2024-www.financetom.com

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025 5:16 AM

June 24 (Reuters) - Nektar Therapeutics ( NKTR ) said on

Tuesday its experimental eczema drug had met the main goals of a

mid-stage study.

Shares of the company were halted in premarket trading.

Previous page： Market Chatter: Groupe Dynamite's 'Canny' IPO to Kick Off More Canadian Deals; Largest Since BLCO Next page： 374Water Prices $12.2 Million Direct Offering

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Market Chatter: Groupe Dynamite's 'Canny' IPO to Kick Off More Canadian Deals; Largest Since BLCO

Nov 15, 2024

09:00 AM EST, 11/15/2024 (MT Newswires) -- Groupe Dynamite Inc. is poised to awaken Canada's long-dormant initial public offering market after an 18-month dry spell, in what bankers are calling a cunningly timed offering that is expected to be the country's biggest debut in nearly three years, Bloomberg reported. Dynamite, a retailer of women's clothing, aims to raise C$300 million...

374Water Prices $12.2 Million Direct Offering

Nov 15, 2024

09:25 AM EST, 11/15/2024 (MT Newswires) -- 374Water (SCWO) said Friday it signed a securities purchase agreement with some investors to buy about $12.2 million worth of its common shares and warrants in a registered direct offering. The company said it has agreed to sell about 9.8 million shares and warrants to buy about 14.7 million shares. The price for...

Boston Scientific Completes Acquisition of Axonics

Nov 15, 2024

09:00 AM EST, 11/15/2024 (MT Newswires) -- Boston Scientific ( BSX ) said Friday that it completed the acquisition of Axonics (AXNX), a medical technology company specializing in devices for urinary and bowel dysfunction. The company said the deal, which has an equity value of $3.7 billion and an enterprise value of $3.3 billion, is expected to be immaterial to...

Toll Brothers Unit, Daiwa House to Develop Luxury Condominium in New York

Nov 15, 2024

09:24 AM EST, 11/15/2024 (MT Newswires) -- Toll Brothers ( TOL ) said Friday that its Toll Brothers City Living unit is partnering with Daiwa House to develop a new nine-story luxury condominium Vista Pointe in the New York metro area. Financial details of the partnership were not disclosed. ...